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Introduction {#sec005}
============

In age-related macular degeneration (AMD), heritability plays a major role in disease development \[[@pone.0156778.ref001]\]. Several risk loci have been identified, but two loci are responsible for approximately 50% of the genetic risk: complement factor H (*CFH*) on chromosome 1q32 and age-related maculopathy susceptibility 2 (*ARMS2*)/HtrA serine peptidase 1 (*HTRA1*) on chromosome 10q26 \[[@pone.0156778.ref002]\].

In AMD, the phenotype of the early stages is characterized by drusen and pigmentary abnormalities. They usually cause little or no visual symptoms, but they are risk factors for progression to advanced AMD \[[@pone.0156778.ref003],[@pone.0156778.ref004]\]. The advanced forms of AMD, namely geographic atrophy (GA) and choroidal neovascularisation (CNV), are the leading causes of visual impairment and blindness among the elderly \[[@pone.0156778.ref005]\]. These findings argue for the concept of a disease continuum starting with few alterations, progressing into an intermediate stage with large drusen, and finally resulting in the late-stage forms GA or neovascular AMD (nAMD). However, there are a lot of patients who develop nAMD with only few early signs of the disease.

The identification of associated genetic variants can help to detect mechanisms of this complex and heterogeneous condition. However, the majority of genetic studies were conducted with late-AMD cases \[[@pone.0156778.ref006]\]. Few studies included early forms of the disease or investigated progression factors \[[@pone.0156778.ref007]--[@pone.0156778.ref010]\]. Therefore, little is known about the role of genetic variants in early AMD or genetic factors driving the progression from early to late AMD. Twin studies indicated a lower heritability for early AMD of only about 35--53% \[[@pone.0156778.ref009]\]. This is significantly lower than the heritability for late AMD of up to 71% \[[@pone.0156778.ref011]\]. In a meta-analysis, only the two major risk genes *CFH* and *ARMS2/HTRA1* were associated with early AMD and the effect sizes were significantly lower than for late AMD \[[@pone.0156778.ref010]\]. However, the reason for these findings is not known. There are several possible explanations. There might be a clinical heterogeneity within the phenotype "early AMD" and some forms might be caused by other genetic factors. It is also possible that not all patients with signs of early AMD will progress to late stages because their retinal changes result from other factors. Another explanation could be different individual effect sizes for early and late AMD \[[@pone.0156778.ref012]\].

Hypothesizing, that there is not only a phenotypic, but also a genotypic disease continuum, we analyze the associations of 18 single nucleotide polymorphisms (SNPs) in individuals showing different AMD stages compared to controls. We also want to evaluate if genetic risk factors vary for different phenotypes. In this case-control study, we additionally want to determine the discrimination ability of genetic factors for unilateral and bilateral stages of early, intermediate, and late AMD.

Methods {#sec006}
=======

In our study, all participants with gradable images and available genetic analysis of the European Genetic Database (EUGENDA, [www.eugenda.org](http://www.eugenda.org/)) were included. EUGENDA is a large case-control database for AMD with participants from the areas around Cologne in Germany and Nijmegen in the Netherlands. Study participants were unrelated, self-described Caucasians, and at least 50 years of age. Controls were allowed to have other eye disease that did not restrict AMD grading. The study was performed in accordance with the tenets of the Declaration of Helsinki and the Medical Research Involving Human Subjects Act (WMO) and was approved by the local ethics committee of the University Hospitals in Cologne and Nijmegen. Written informed consent was obtained from all participants.

Grading {#sec007}
-------

AMD staging was performed by certified graders (TS and LE) according to the standard protocol of the Cologne Image Reading Center (CIRCL). Graders were blinded to the aims of this study. Grading of retinal images included stereo fundus photographs, fluorescein angiograms and SDOCTs. Controls were allowed to have only small drusen or pigmentary abnormalities with not more than 9 small drusen in the Early Treatment of Diabetic Retinopathy Study (ETDRS) grid. Control cases were additionally graded for changes of the outer retina in the whole SDOCT 6 mm x 4 mm volume scans (Spectralis SDOCT, Heidelberg Engineering, Heidelberg, Germany, performed by TS and EV). Eyes were termed as supercontrols, when both eyes showed an intact external limiting membrane, ellipsoid zone and retinal pigment epithelium (RPE)-Bruch´s complex.

Early AMD was classified by the presence of at least 10 small drusen (\<63 μm) and pigmentary changes or the presence of 1--14 intermediate (63--124 μm) drusen in the ETDRS grid. Intermediate AMD was classified by the presence of ≥15 intermediate drusen or any large drusen (≥125 μm in diameter). Advanced AMD with geographic atrophy (GA) was defined as AMD with subfoveal atrophy of the RPE of at least 175μm diameter. Neovascular AMD (nAMD) was characterized by choroidal neovascularization (CNV) secondary to AMD. AMD staging was performed for both eyes separately and individuals were categorized in supercontrols, no AMD, unilateral early AMD, bilateral early AMD, unilateral intermediate AMD, bilateral intermediate AMD, unilateral GA, bilateral GA, unilateral nAMD, bilateral nAMD, late AMD mixed type. Late AMD mixed type was defined as CNV in one eye and GA in the other eye. In cases termed "unilateral", the grading differed between both eyes. The classification was then based on the eye with the more severe AMD grading. (e.g. unilateral intermediate AMD could have no AMD or early AMD in the fellow-eye). In late AMD, no ranking of severity between GA and nAMD was made.

Genotyping {#sec008}
----------

Genomic DNA was extracted from peripheral blood samples using standard procedures. Eighteen SNPs in or near 13 AMD associated risk genes were chosen representing the major loci associated with AMD which are *CFH*, *ADAMTS9-AS2*, *COL8A1*, *CFI*, *C9*, *C2-CFB-SKIV2L*, *VEGFA*, *TNFRSF10A*, *TGFBR1*, *ARMS2-HTRA1*, *B3GALTL*, *RAD51B*, *LIPC*, *CETP*, *C3*, *APOE*, *SYN3-TIMP3*, *SLC16A8*, *COL4A3*, *PRLR-SPEF2*, *PILRB-PILRA*, *KMT2E-SRPK2*, *TRPM3*, *MIR6130-RORB*, *ABCA1*, *ARHGAP21*, *RDH5-CD63*, *ACAD10*, *CTRB2-CTRB1*, *TMEM97-VTN*, *NPLOC4-TSPAN10*, *CNN2*, *MMP9*, *C20orf85*. \[[@pone.0156778.ref013]\]. Genotyping of SNPs in the *ARMS2* (rs10490924), *CFH* (rs1061170, rs800292, rs12144939), *CFI* (rs10033900), *C3* (rs2230199, rs1047286), *CFB* (rs4151667, rs641153), *TIMP3* (rs9621532), *APOE* (rs2075650, rs4420638), *CETP* (rs3764261), *VEGFA* (rs943080), *TGFBR1* (rs334353), *SKIV2L* (rs429698), *RAD51B* (rs8017304) *and TNFRSF10A* (rs1327806) genes were carried out as previously described \[[@pone.0156778.ref014]\]. With an allele-specific PCR, a fluorescent signal is generated through the use of universal labeled primers, which can be quantified directly from microplates using standard plate readers. The assay is conducted in closed-tube format to reduce the potential for contamination to a minimum \[[@pone.0156778.ref014]\].

Statistical analysis {#sec009}
--------------------

Calculations were performed using SPSS software version 21.0 (IBM Software and Systems, Armonk, NY, USA). Associations between AMD severity stages and SNPs were calculated by univariate logistic regression analyses. For analysis, SNPs were categorized into "wild type", the "heterozygous" risk variant, and the "homozygous" risk variant. All analyses were adjusted for age. Associations of other known risk factors (gender, smoking status, arterial hypertension and diabetes) were tested using Chi^2^-test, age was tested using an analysis of variance (ANOVA). Armitage's trend test between the severity stages no AMD, unilateral early AMD, bilateral early AMD, unilateral intermediate AMD, bilateral intermediate AMD, unilateral late AMD and bilateral late AMD for each SNP (wild type / heterozygous vs. homozygous and wild type vs. heterozygous / homozygous) was performed using SAS software version 9.3. Power analysis was calculated with nQuery Advisor 7.0.

Odds ratios (OR) and 95% confidence intervals (CI) were calculated. P-values are two-sided and were analyzed with the Chi^2^-test. P-values \<0.05 were considered statistically significant. For each severity stage, multivariate regression models were computed including all SNPs and age of participants. Variables were not categorized for better visualization and comparability of the results. The area under the receiver operating characteristic curve (AUC) was calculated to check the genetic discriminative ability between cases of different AMD stages and healthy controls.

Patients with unilateral nAMD were analyzed for associations with rs10490924 in *ARMS2* and rs1061170 in *CFH by* univariate regression analysis and models were calculated by multivariate regression including both SNPs and age. Patients were differentiated based on disease severity in the second eye with "no AMD", "early AMD", and "intermediate AMD". Additionally, Armitage's trend test was performed for these severity stages of the fellow eye and both SNPs.

Results {#sec010}
=======

In the analysis, we included 3444 participants. Demographics and grading results are shown in [Table 1](#pone.0156778.t001){ref-type="table"} and [Table 2](#pone.0156778.t002){ref-type="table"}. For power calculation, Chi^2^-test was used comparing the patients with no AMD (n = 1673) to any other group (type I error = 5%). We would be able to detect odds ratios (e.g. wild type and heterozygous vs. homozygous) of 1.5 or greater with a power of 80% if the sample size in the other group reached at least n = 218.

10.1371/journal.pone.0156778.t001

###### Demographics.

![](pone.0156778.t001){#pone.0156778.t001g}

                          No AMD               Early AMD           Intermediate AMD     Late AMD            p-value
  ----------------------- -------------------- ------------------- -------------------- ------------------- ----------------------------------------------
  Age (range)             69.0±7.9 (50--100)   72.1±8.0 (50--99)   73.8±9.0 (52--100)   76.9±8.3 (50--98)   \<0.001[\*](#t001fn001){ref-type="table-fn"}
  Female Sex              956/1673 (57.1%)     226/379 (59.6%)     209/333 (62.8%)      636/1059 (60.1%)    0.18[\*\*](#t001fn002){ref-type="table-fn"}
  Smoking (ever)          914/1610 (56.8%)     188/357 (52.7%)     184/309 (59.5%)      539/886 (60.8%)     0.04[\*\*](#t001fn002){ref-type="table-fn"}
  Arterial Hypertension   644/1644 (39.2%)     138/372 (37.1%)     129/322 (40.1%)      344/967 (35.6%)     0.25[\*\*](#t001fn002){ref-type="table-fn"}
  Diabetes                126/1644 (7.7%)      35/372 (9.4%)       25/322 (7.8%)        113/967 (11.7%)     0.005[\*\*](#t001fn002){ref-type="table-fn"}

\*analyzed with ANOVA

\*\*analyzed with Chi^2^-test

10.1371/journal.pone.0156778.t002

###### Grading results.

![](pone.0156778.t002){#pone.0156778.t002g}

  AMD staging                     n
  ------------------------------- ----------
  supercontrols                   435
  **total no AMD**                **1673**
  unilateral early AMD            240
  bilateral early AMD             139
  **total early AMD**             **379**
  unilateral intermediate AMD     132
  bilateral intermediate AMD      201
  **total intermediate AMD**      **333**
  unilateral neovascular AMD      431
  bilateral neovascular AMD       462
  unilateral geographic atrophy   41
  bilateral geographic atrophy    70
  mixed type                      55
  **total late AMD**              **989**
  **total group**                 **3444**

AMD = age-related macular degeneration, late AMD, mixed type shows neovascular AMD in one eye and geographic atrophy in the fellow-eye.

Distribution of SNPs and results of the trend analyses are summarized in [Table 3](#pone.0156778.t003){ref-type="table"} for rs10490924 in *ARMS2* and rs1061170 in *CFH*. Results of additional SNPs are presented in [S1 Table](#pone.0156778.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0156778.t003

###### Distribution of single nucleotide polymorphisms rs10490924 in *ARMS2* and rs1061170 in *CFH* and trend test of AMD severity stages (data of other SNPs is shown in [S1 Table](#pone.0156778.s001){ref-type="supplementary-material"}).

![](pone.0156778.t003){#pone.0156778.t003g}

  AMD staging                     *ARMS2* (rs10490924)                                                                              *CFH* (rs1061170)
  ------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------
  no AMD                          GG: 961 (57.9%)                                                                                   TT: 646 (39.0%)
                                  GT: 606 (36.5%)                                                                                   TC: 796 (48.1%)
                                  TT: 92 (5.5%)                                                                                     CC: 214 (12.9%)
  unilateral early AMD            GG: 119 (50.0%)                                                                                   TT: 88 (37.4%)
                                  GT: 105 (44.1%)                                                                                   TC: 116 (49.4%)
                                  TT: 14 (5.9%)                                                                                     CC: 31 (13.2%)
  bilateral early AMD             GG: 83 (60.6%)                                                                                    TT: 42 (22.0%)
                                  GT: 43 (31.4%)                                                                                    TC: 69 (46.9%)
                                  TT: 11 (8.0%)                                                                                     CC: 28 (20.1%)
  unilateral intermediate AMD     GG: 60 (45.5%)                                                                                    TT: 47 (35.6%)
                                  GT: 56 (42.4%)                                                                                    TC: 58 (43.9%)
                                  TT: 16 (12.1%)                                                                                    CC: 27 (20.5%)
  bilateral intermediate AMD      GG: 86 (43.2%)                                                                                    TT: 44 (22.0%)
                                  GT: 85 (42.7%)                                                                                    TC: 91 (45.5%)
                                  TT: 28 (14.1%)                                                                                    CC: 65 (32.5%)
  unilateral neovascular AMD      GG: 147 (34.6%)                                                                                   TT: 81 (19.1%)
                                  GT: 180 (42.4%)                                                                                   TC: 196 (46.2%)
                                  TT: 98 (23.1%)                                                                                    CC: 147 (34.7%)
  bilateral neovascular AMD       GG: 122 (26.8%)                                                                                   TT: 90 (19.8%)
                                  GT: 210 (46.2%)                                                                                   TC: 204 (44.8%)
                                  TT: 123 (27.0%)                                                                                   CC: 161 35.4%)
  unilateral geographic atrophy   GG: 16 (39.0%)                                                                                    TT: 7 (17.1%)
                                  GT: 15 (36.6%)                                                                                    TC: 23 (56.1%)
                                  TT: 10 (24.4%)                                                                                    CC: 11 (26.8%)
  bilateral geographic atrophy    GG: 21 (30.4%)                                                                                    TT: 7 (10.0%)
                                  GT: 32 (46.4%)                                                                                    TC: 39 (55.7%)
                                  TT: 16 (23.2%)                                                                                    CC: 24 (34.3%)
  late AMD mixed type             GG: 14 (25.5%)                                                                                    TT: 9 (16.4%)
                                  GT: 26 (47.3%)                                                                                    TC: 23 (41.8%)
                                  TT: 15 (27.3%)                                                                                    CC: 23 (41.8%)
  trend test (p-value)            \<0.0001[^a^](#t003fn002){ref-type="table-fn"} / \<0.0001[^b^](#t003fn003){ref-type="table-fn"}   \<0.0001[^c^](#t003fn004){ref-type="table-fn"} / \<0.0001[^d^](#t003fn005){ref-type="table-fn"}

AMD = age related macular degeneration

a: GG + GT vs. TT

b: GG vs. GT + TT

c: TT + TC vs. CC

d: TT vs. TC + CC

Univariate regression analysis of SNPs {#sec011}
--------------------------------------

Univariate regression analysis of SNPs was performed for all AMD severity stages. Detailed results are outlined for main risk SNPs in *ARMS2* and *CFH* in [Table 4](#pone.0156778.t004){ref-type="table"} and for additional SNPs in [S2 Table](#pone.0156778.s002){ref-type="supplementary-material"}. Supercontrols showed no significant associations compared to subjects with no AMD. However, *ARMS2* and *CFH* rs1061170 showed lower OR in supercontrols but mostly without reaching significance. In general, with increasing severity and bilateralism more SNPs were associated with the disease and higher odds ratios were found.

10.1371/journal.pone.0156778.t004

###### Univariate regression analysis for each severity stage with results for SNPs rs10490924 in *ARMS2* and rs1061170 in *CFH* (data of other SNPs is shown in [S2 Table](#pone.0156778.s002){ref-type="supplementary-material"}).

![](pone.0156778.t004){#pone.0156778.t004g}

  AMD staging                     *ARMS2* (rs10490924)      *CFH* (rs1061170)
  ------------------------------- ------------------------- ------------------------
  supercontrols                   0.45, p = 0.03            0.65, p = 0.08
                                  0.52, p = 0.09            0.66, p = 0.08
  unilateral early AMD            1.47, p = 0.008           1.08, p = 0.61
                                  1.34, p = 0.33            1.10, p = 0.68
  bilateral early AMD             0.87, p = 0.49            1.40, p = 0.10
                                  1.55, p = 0.20            2.17, p = 0.003
  unilateral intermediate AMD     1.59, p = 0.02            1.03, p = 0.90
                                  3.36, p = 9.44x10^-5^     1.80, p = 0.02
  bilateral intermediate AMD      1.69, p = 0.002           1.70, p = 0.006
                                  4.14, p = 1.68x10^-8^     4.85, p = 3.56x10^-13^
  unilateral neovascular AMD      2.08, p = 1.21x10^-8^     2.04, p = 1.35x10^-6^
                                  8.23, p = 1.00x10^-13^    5.97, p = 1.00x10^-13^
  bilateral neovascular AMD       3.18, p = 1.01x10^-13^    2.07 p = 3.56x10^-6^
                                  14.86, p = 1.00x10^-13^   6.86 p = 1.00x10^-13^
  unilateral geographic atrophy   1.60, p = 0.21            2.88, p = 0.02
                                  8.28, p = 1.60x10^-6^     5.52, p = 0.001
  bilateral geographic atrophy    2.54, p = 0.001           4.76, p = 0.0002
                                  9.64, p = 8.77x10^-10^    11.97, p = 3.53x10^-8^
  late AMD mixed type             3.42, p = 0.001           2.40, p = 0.04
                                  16.93, p = 5.21x10^-11^   9.93 p = 1.06x10^-7^

First line: heterozygous variant, second line: homozygous variant showing odds ratio and p-value. Analysis adjusted for age, reference: no AMD; SNPs = single nucleotide polymorphisms, AMD = age-related macular degeneration, interm. = intermediate, nAMD = neovascular AMD, GA = geographic atrophy.

Multivariate regression model for each severity stage {#sec012}
-----------------------------------------------------

In the multivariate regression model, all 18 SNPs were included and age was used as a covariate. Models were calculated for each AMD stage with "no AMD" as the reference variable. Increasing severity stages of AMD showed an almost continuous increase of odds ratios for *ARMS2* (rs10490924) and *CFH* (rs1061170) ([Table 5](#pone.0156778.t005){ref-type="table"}). The influence of other SNPs was considerably lower, rarely reaching significant p-values ([S3 Table](#pone.0156778.s003){ref-type="supplementary-material"}). The AUC showed increasing values with increasing AMD severity. Bilateral disease showed a higher AUC than unilateral disease within each severity level. Highest genetic discrimination between controls and cases (AUC = 0.957) was observed for late AMD mixed type. Details are shown in [Table 6](#pone.0156778.t006){ref-type="table"}.

10.1371/journal.pone.0156778.t005

###### Multivariate regression model for each severity stage with results for SNPs rs10490924 in *ARMS2* and rs1061170 in *CFH* (data of other SNPs is shown in [S3 Table](#pone.0156778.s003){ref-type="supplementary-material"}).

![](pone.0156778.t005){#pone.0156778.t005g}

  AMD staging                     *ARMS2* (rs10490924)                  *CFH* (rs1061170)
  ------------------------------- ------------------------------------- ------------------------------------
  unilateral early AMD            1.32 (1.02--1.72), p = 0.04           1.18 (0.86--1.63), p = 0.30
  bilateral early AMD             1.08 (0.76--1.54), p = 0.68           1.20 (0.80--1.79), p = 0.38
  unilateral intermediate AMD     1.97 (1.41--2.76), p = 7.91x10^-5^    1.28 (0.85--1.94), p = 0.23
  bilateral intermediate AMD      2.83 (2.07--3.86), p = 6.06x10^-6^    1.39 (0.97--2.00), p = 0.08
  unilateral neovascular AMD      3.01 (2.39--3.79), p = 6.24x10^-21^   1.80 (1.34--2.41), p = 9.36x10^-5^
  bilateral neovascular AMD       4.76 (3.58--6.32), p = 6.49x10^-27^   1.75 (1.25--2.46), p = 6.06x10^-6^
  unilateral geographic atrophy   4.86 (2.45--9.62), p = 5.98x10^-6^    1.50 (0.64--3.52), p = 0.36
  bilateral geographic atrophy    3.36 (1.79--6.29), p = 0.0002         1.71 (0.78--3.72), p = 0.18
  late AMD mixed type             4.27 (2.22--8.22), p = 1.36x10^-5^    2.45 (1.04--5.78), p = 0.04

Odds ratios and 95% Confidence intervals are shown, reference: no AMD.

10.1371/journal.pone.0156778.t006

###### Area under the curve (AUC) of risk models in different AMD severity stages.

![](pone.0156778.t006){#pone.0156778.t006g}

  AMD staging                     AUC     95% CI         p-value
  ------------------------------- ------- -------------- ---------------
  unilateral early AMD            0.629   0.586--0.672   3.55x10^-8^
  bilateral early AMD             0.669   0.611--0.727   2.85x10^-8^
  unilateral intermediate AMD     0.789   0.747--0.831   1.70x10^-22^
  bilateral intermediate AMD      0.831   0.792--0.870   1.45x10^-36^
  unilateral neovascular AMD      0.835   0.805--0.865   9.86x10^-66^
  bilateral neovascular AMD       0.917   0.896--0.937   8.93x10^-104^
  unilateral geographic atrophy   0.902   0.826--0.979   3.70x10^-11^
  bilateral geographic atrophy    0.933   0.893--0.974   7.15x10^-19^
  late AMD mixed type             0.957   0.923--0.991   2.33x10^-22^

AMD = age-related macular degeneration, CI = confidence interval

Severity levels of fellow-eyes in nAMD {#sec013}
--------------------------------------

Univariate regression analysis for rs10490924 in *ARMS2* and rs1061170 in *CFH* was performed for cases with nAMD in the study eye and different severity stages of the fellow-eye. With increasing severity of the fellow-eye, increasing ORs were found ([Table 7](#pone.0156778.t007){ref-type="table"}). A regression model that included both SNPs revealed similar results (data not shown). The trend analysis showed p = 0.009 (GG + GT vs. TT) and p = 0.001 (GG vs. GT + TT) for rs10490924 in *ARMS2* and p = 0.01 (TT + TC vs. CC) and p = 0.03 (TT vs. TC + CC) for rs1061170 in *CFH*, indicating that the genetic associations increase with rising disease severity in the fellow-eye in unilateral nAMD.

10.1371/journal.pone.0156778.t007

###### Univariate regression analysis for SNPs rs10490924 in ARMS2 and rs1061170 in CFH in patients with unilateral nAMD and different severity stages of the fellow-eye.

![](pone.0156778.t007){#pone.0156778.t007g}

  Staging of fellow-eye   *ARMS2* (rs10490924)                 *CFH* (rs1061170)
  ----------------------- ------------------------------------ ------------------------------------
  No AMD                  1.66 (1.19--2.32) p = 0.03           1.74 (1.27--2.39) p = 0.01
  Early AMD               2.54 (1.87--3.46) p = 3.30x10^-9^    2.35 (1.73--3.19) p = 4.72x10^-8^
  Intermediate AMD        3.45 (1.08--1.12) p = 4.00x10^-29^   3.01 (2.42--3.74) p = 2.82x10^-23^

Odds ratios and 95% confidence intervals are shown, analysis adjusted for age. reference: no AMD; SNP = single nucleotide polymorphism, AMD = age-related macular degeneration.

Discussion {#sec014}
==========

While genetic risk factors for late AMD are well established, less is known for early stages of the disease. In this study, we showed that genetic associations were stronger with increasing disease severity. Genetic discrimination between AMD and controls was higher for late stages of the disease and was also higher for bilateral compared to unilateral cases. For bilateral late AMD mixed type the discrimination was almost perfect.

It has been previously shown that genetic factors differ between early and late AMD \[[@pone.0156778.ref007],[@pone.0156778.ref008]\]. Our results support these findings in more detail and suggest that there is a disease continuum from early to late AMD based on genetic factors.

We also found that only few loci were associated with early disease as opposed to late-stage disease. These results are in line with other studies showing differences in heritability \[[@pone.0156778.ref009],[@pone.0156778.ref011]\] and effect size \[[@pone.0156778.ref010]\] between early and late AMD.

However, all AMD stages shared some risk variants. For example, risk variants in CFH and ARMS2 conferred a risk from early to late stages of the disease. In addition, it is possible that there are additional yet unknown unique risk variants driving the onset and the progression of AMD. Despite of large genome-wide association studies, these factors have not yet been detected. Therefore, other possibilities have to be taken into account. An explanation might be that different variants produce synergistic effects for progression of the disease, but the identification of those patterns would be very challenging. Another explanation could be a higher phenotypic and genetic heterogeneity of early AMD. Maybe, the time of onset of AMD is driven by different pathways in different subjects. This would lower the effect sizes of a particular risk variant on the population level despite similar effect sizes in individuals.

Additionally, there may be some forms of „early AMD"that do not progress to late AMD although their clinical appearance can not yet be distinguished from other, progressing forms of early AMD. On the other hand, studies on very old individuals indicate that the majority of patients will eventually develop late AMD \[[@pone.0156778.ref015]\].

In this study, only *CFH* variants showed an effect in early AMD in univariate analyses. The role of *CFH* in early AMD was also described in other reports \[[@pone.0156778.ref016],[@pone.0156778.ref017]\]. In the ARED study, the involvement of the complement system was discussed to be associated with early drusen formation \[[@pone.0156778.ref018]\]. The effect of risk variants in other genes of the complement system such as *C3* and *CFB* as well as other pathways became significant only in intermediate and late AMD. This is also consistent with reports showing an involvement of these genes with late AMD \[[@pone.0156778.ref019],[@pone.0156778.ref020]\].

Likewise, in our multivariate model, significant associations were only seen for the SNPs in *CFH* (rs800292 and rs12144939), *ARMS2* (rs10490924), and rs3764261 in the Cholesterylester transfer gene \[[@pone.0156778.ref021]--[@pone.0156778.ref023]\]. This again highlights the importance of CFH and ARMS2 in all stages of AMD.

We also analyzed very subtle age-related changes in SDOCT images. We compared persons without any retinal changes ("supercontrols") with persons having minor abnormalities but not yet being classified as AMD ("no AMD"). Both groups showed no significant genetic difference. This goes in line with the findings of Ferris at al, where small drusen were called druplets to underline that they are normal aging changes without a higher risk for developing AMD \[[@pone.0156778.ref024]\]. However, although not reaching significance risk variants showed lower OR in supercontrols, which is suggestive that even these small changes are first signs of the disease and are at least partially driven by common AMD risk variants.

In this study, we demonstrated that the phenotype of both eyes and not only the worst affected may influence genetic susceptibility. We observed higher discrimination between cases and controls and higher genetic associations with more severe involvement of the fellow-eye. Previously published AMD prediction models include demographic, genetic and environmental factors for AMD, but the associations between phenotype and genotype are mostly based on the more severely affected eye \[[@pone.0156778.ref025]\]. However, this conventional case-control approach of association testing does not provide all the information of the complex disease.

Our study has several limitations: the design as a case-control study has no follow-up and therefore prediction models for AMD progression cannot be provided. Our results suggest an increased genetic influence of known genetic factors on late AMD compared to early AMD, but they are not able to explain the cause. Additionally, the effect of age on AMD development is enormous and despite an adjustment for age in our calculations there might be a remaining influence of age in our analysis. Further studies containing large numbers of cases with GA and late AMD mixed type are needed to validate our results.

Strength of our study was the use of multimodal imaging for AMD staging combining fundus photographs and SDOCT. This guaranteed a superior differentiation of phenotypes compared to the majority of genetic studies.

In summary, genetic risk variants primarily established for late AMD showed reduced effects on early stages of the disease. Associations of these variants with AMD became stronger with increasing disease severity, which also led to an increasing discriminative ability. Our results also underline the importance of the second eye in AMD patients because the genetic predisposition was also associated with the disease severity of the fellow-eye. Future studies are needed to identify the processes leading to the onset of early AMD and the progression to late AMD in order to develop treatments to prevent vision loss.
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